Selection of reperfusion therapy for individual patients with evolving myocardial infarction

European Heart Journal

Volumn 18, Issue 9, 1997, Pages 1371-1381

  Boersma, H ^a   Califf, R ^a   Collins, R ^a   Deckers, J W ^a   Simoons, M L ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; RETEPLASE; SARUPLASE; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; BRAIN HEMORRHAGE; CORONARY ARTERY DILATATION; COST BENEFIT ANALYSIS; DRUG CHOICE; FIBRINOLYTIC THERAPY; HEALTH CARE COST; HEART; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE REPERFUSION; HUMAN; MEDICAL DECISION MAKING; MORBIDITY; MORTALITY; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; STROKE; SURVIVAL TIME; TIME;

EID: 0030765443     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.eurheartj.a015461     Document Type: Review

References (62)